{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-24-000023","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.497383+00:00","generated_at":"2026-05-31T10:43:05.446478+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prestige Consumer Q1 revenue $267.1M beats expectations; reaffirms FY2025 outlook","bullets":["Q1 GAAP EPS $0.98, adjusted EPS $0.90; revenue down 4.4% YoY but ahead of internal plan.","Cash from operations $54.8M (+13.9% YoY); reduced debt $35M and repurchased $26M in shares.","North American OTC revenue $232.3M (-5.6%); International OTC $34.8M (+5.0% driven by Hydralyte).","FY2025 guidance reaffirmed: revenue $1.125-$1.140B, adjusted EPS $4.40-$4.46, FCF $240M+.","CEO cited earlier supply of Clear Eyes products as primary driver of Q1 beat over expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-24-000023","json":"https://secwatch.observer/filing/0001295947-24-000023.json","markdown":"https://secwatch.observer/filing/0001295947-24-000023.md","text":"https://secwatch.observer/filing/0001295947-24-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594724000023/0001295947-24-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594724000023/pbh-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:43:05.446478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}